Climate change impacts on coastal lakes: an evaluation of the impact on Vembanad, Chilka and Pulicat lakes and their resources

Bivalves play key role in ecosystem stabilisation due to inherent filter feeding capability and clams are important components of soft bottom benthic communities. In the Tuticorin Bay, mass mortality of fishes and shellfishes was observed in Februay 2008. The probable cause for the large scale mortality has been indicated as increased levels of ammonia (Asha et al., 2009). A rapid survey was conducted in the bay to assess the impact on the bivalve fauna

भारत के दक्षिण-पशिचम तट के अष्टमुडी झील में अवसाद और पानी की गुणता के परिवेश में सीपी संस्तरों का निर्धारण

कृपया पूरा लेखा पढ

Sediment quality evaluation towards developing scientific restoration protocol for mangroves

The role of mangroves as bio-shields and as critical habitats are being increasingly recognised and proved in the recent years. However, urbanisation and other anthropogenic activities have reduced the mangrove cover of most coastal areas. To overcome this, restoration programs are planned in several areas. Planting of mangrove seedlings without considering the ecological criteria suitable for the biological success of the mangroves, have given poor success rate

Fishery Management Plan for Ashtamudi Lake Clam Resources അഷ്ടമുടിക്കായലിലെ കക്ക സമ്പത്ത് ഒരു പരിപാലന പദ്ധതി

Th e Central Marine Fisheries Research Institute (CMFRI) has been studying the exploitation and biology of the key clam resource in the Ashtamudi Lake ecosystem from the late nineteen seventies. As a result of such concerted studies, an intervention for the scientifi c management of the clam resources could be made in the nineteen eighties, and ever since then, a sustained fi shery for the short-neck clam is being practiced by the fi shers. Realizing that the short-neck clam fi sheries is one of the few scientifi cally managed fi sheries in India, the World Wide Fund for Nature (WWF, India) initiated steps to get the fi sheries certifi ed or ecolabelled as per the criteria of the Marine Stewardship Council (MSC). Th is survey report and fi sheries management plan is a direct result of the WWF’s positive steps and the WWF has provided logistic support for the survey conducted by the CMFRI. We would like to place on record our sincere thanks to Mr. Vinod Malayilethu, Senior Coordinator, Marine Conservation Programme, WWF, India for all support and help. We are also thankful to the Director, CMFRI for facilities, constructive criticism and encouragement to bring out this work as a special publication of the institute

Gastrointestinal Stromal Tumors (GIST): Is the Incidence rising in India? —A Hospital Based Analysis

Context: Gastrointestinal stromal tumours (GISTs) are rare tumours of the gastrointestinal tract (GI) but they are the most common amongst the mesenchymal tumours. However, there are very few published articles on patients with the diagnoses of GISTs from the Indian subcontinent and particularly from the eastern part of India. Also we noted an increased number of patients with the diagnosis of GISTs in our clinical practice compared to the past decade and have observed an increased incidence of tumours arising from the small bowel and large bowel compared to the stomach. Aims: To study the incidence of symptomatic GISTs, the demographic details, clinical presentations, the histopathological and immunohistochemistry features and survival of the patients and response of these tumours to imatinib therapy. Settings and Design: A retrospective study based on hospital registry conducted in the Departments of Radiotherapy and General Surgery, IPGME&R- SSKM Hospital, Kolkata and NRSMCH, Kolkata. Methods & Material: Cross sectional imaging and endoscopic evaluations were used to diagnose the tumours. Tumor categorization required microscopic and immunohistochemistry studies for c-Kit, DOG-1 and other tumor markers. High risk group tumours were treated with imatinib 400 mg/day for 3 years duration. Statistical Analysis:Incidence of GISTs was analyzed using Pearson Chi-square test and Survival was analyzed using Kaplan-Meier survival curve and Pearson Chi-square test. Results: Incidence of GISTs in 2010-2011 was 0.37% whereas in 2018-2019 it was 2.48% with 85% increase, p value of <0.001. The commonest tumor location was in the small bowel (40.7%), followed by stomach (25.4%) and colo-rectum (10.2%). Mean duration of imatinib therapy was 19.33 months with 84% overall survival. Estimated three-year OS (overall survival) was 73.6%. Estimated mean OS was 66±5.39 months with 95% CI 55.6-76.7. Mean survival of patients with metastatic disease on imatinib therapy was 16.88 months with p=0.000. Primary response to imatinib therapy was observed in 93.87% (43/46) patients. Patients developing disease progression on imatinib were treated with Sunitinib and they demonstrated partial response. Conclusion: We have documented an increased incidence of gastrointestinal stromal tumours and there is increased proportion of small bowel and colorectal tumours compared to gastric tumours. Keywords: Gastrointestinal Stromal Tumours, Incidence, cKIT, DOG-1, Imatinib

Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.

Aripiprazole lauroxil (AL), a new long-acting injectable antipsychotic, demonstrated safety and efficacy in treating acute exacerbation symptoms of schizophrenia in a 12-week placebo-controlled trial of two doses of AL (441mg and 882mg) administered every 4weeks. We performed a post hoc analysis of this trial to evaluate the efficacy of AL in the subgroup of patients with severe psychotic symptoms, defined as those with baseline Positive and Negative Syndrome Scale (PANSS) Total score above the median score of 92 (n=309). Change from baseline to Day 85 in PANSS Total score; Positive, Negative, and General Psychopathology subscale scores; and overall response rate were assessed. Statistically significant and clinically meaningful improvements in PANSS Total score were demonstrated with AL 441mg and AL 882mg, with placebo-adjusted differences of -14.7 (p<0.0001) and -16.6 (p<0.0001), respectively. Significant and clinically meaningful findings with both doses of AL were also demonstrated for the PANSS subscales and responder rates. Overall responder rates at Day 85 were significantly greater for AL 441mg (49%; p<0.001) and 882 mg (61%; p<0.001) groups vs. placebo (18%). Common adverse events (>5%) were schizophrenia, akathisia, headache, insomnia, and anxiety. AL demonstrated robust efficacy in treatment of the subgroup of patients experiencing severe psychotic symptoms. Both doses (441mg and 882mg) were effective, with numerically greater improvement in symptoms and proportion of responders favoring the higher dose arm. Both doses had a side effect profile consistent with the known safety profile of aripiprazole

Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.

Aripiprazole lauroxil (AL), a new long-acting injectable antipsychotic, demonstrated safety and efficacy in treating acute exacerbation symptoms of schizophrenia in a 12-week placebo-controlled trial of two doses of AL (441mg and 882mg) administered every 4weeks. We performed a post hoc analysis of this trial to evaluate the efficacy of AL in the subgroup of patients with severe psychotic symptoms, defined as those with baseline Positive and Negative Syndrome Scale (PANSS) Total score above the median score of 92 (n=309). Change from baseline to Day 85 in PANSS Total score; Positive, Negative, and General Psychopathology subscale scores; and overall response rate were assessed. Statistically significant and clinically meaningful improvements in PANSS Total score were demonstrated with AL 441mg and AL 882mg, with placebo-adjusted differences of -14.7 (p<0.0001) and -16.6 (p<0.0001), respectively. Significant and clinically meaningful findings with both doses of AL were also demonstrated for the PANSS subscales and responder rates. Overall responder rates at Day 85 were significantly greater for AL 441mg (49%; p<0.001) and 882 mg (61%; p<0.001) groups vs. placebo (18%). Common adverse events (>5%) were schizophrenia, akathisia, headache, insomnia, and anxiety. AL demonstrated robust efficacy in treatment of the subgroup of patients experiencing severe psychotic symptoms. Both doses (441mg and 882mg) were effective, with numerically greater improvement in symptoms and proportion of responders favoring the higher dose arm. Both doses had a side effect profile consistent with the known safety profile of aripiprazole

Not Available

Not AvailableThe role of mangroves as bio-shields and as critical habitats are being increasingly recognised and proved in the recent years. However, urbanisation and other anthropogenic activities have reduced the mangrove cover of most coastal areas. To overcome this, restoration programs are planned in several areas. Planting of mangrove seedlings without considering the ecological criteria suitable for the biological success of the mangroves, have given poor success ratesNot Availabl

Not Available

Not AvailableThe role of mangroves as bio-shields and as critical habitats are being increasingly recognised and proved in the recent years. However, urbanisation and other anthropogenic activities have reduced the mangrove cover of most coastal areas. To overcome this, restoration programs are planned in several areas. Planting of mangrove seedlings without considering the ecological criteria suitable for the biological success of the mangroves, have given poor success ratesNot Availabl